DURECT Corporation (DRRX)
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.
The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder.
It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally.
The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited.
DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
|IPO Date||Sep 28, 2000|
|Industry||Drug Manufacturers - Specialty & Generic|
|CEO||Dr. James E. Brown D.V.M.|
10260 Bubb Rd
Cupertino, California 95014
|Fiscal Year||January - December|
|Dr. James E. Brown D.V.M.||Co-Founder, Chief Executive Officer, President and Director|
|Judy R. Joice||Senior Vice President of Operations and Corporate Quality Assurance|
|Dr. Norman L. Sussman M.D.||Chief Medical Officer|
|Timothy M. Papp M.B.A.||Chief Financial Officer and Secretary|
|Jian Li M.B.A.||Interim Principal Accounting Officer, Senior Vice President of Finance, Corporate Controller and Secretary|
|Dr. Andrew R. Miksztal Ph.D.||Vice President of Pharmaceutical Research & Development and Principal Scientist|
|Steve Helmer J.D.||Vice President and Chief Patent Counsel|
|Dr. WeiQi Lin M.D., Ph.D.||Executive Vice President of Research & Development and Principal Scientist|
|Keith L. Lui M.B.A.||Senior Vice President of Business Development, Commercial and Medical Affairs|
|Dr. Su Il Yum Ph.D.||Executive Officer|
Latest SEC Filings
|Nov 14, 2023||10-Q||Quarterly Report|
|Nov 13, 2023||8-K||Current Report|
|Nov 7, 2023||8-K||Current Report|
|Sep 7, 2023||8-K||Current Report|
|Aug 10, 2023||S-8||Securities to be offered to employees in employee benefit plans|
|Aug 10, 2023||10-Q||Quarterly Report|
|Aug 9, 2023||8-K||Current Report|
|Jul 21, 2023||8-K||Current Report|
|Jul 21, 2023||424B5||Filing|
|Jun 22, 2023||8-K||Current Report|